Rakuten Medical, Inc.
900 Concar Dr, Suite 200
Tel: (858) 925-5619
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its IlluminoxTM technology platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company's first investigational product developed on the Illuminox platform, ASP-1929, has achieved Fast Track designation from the FDA and Sakigake Designation from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. Headquartered in the United States, Rakuten Medical has 6 locations in 5 countries, Japan, the Netherlands, Germany and Taiwan. For more information, visit www.rakuten-med.com.
27 articles with Rakuten Medical, Inc.
Rakuten Medical Japan Announces Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux® IV Infusion 250mg (cetuximab saratolacan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.
Rakuten Medical, Inc. announced today the acquisition of Medlight SA. Medlight produces and commercializes a large range of catheters and diffusers for optical light delivery. The terms of
Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate
Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product c
Rakuten Medical Receives Conditional Early Approval Designation from Japanese Health Ministry for its Lead Drug, ASP-1929, to Treat Recurrent Head & Neck Cancer
Rakuten Medical, Inc. (Rakuten Medical) today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has notified Rakuten Medical that its lead drug ASP-1929 will be reviewed under the Conditional Early Approval System (CEAS). Compared to standard review the CEAS speeds up the approval process, bringing potentia
Rakuten Medical Presents Data Characterizing how Photoimmunotherapy Induces Cancer Cell Death and Enhances the Immune Response Preclinically
Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II. These studies further demonstrate t
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments
Rakuten Medical, Inc. (Rakuten Medical) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary Illuminox ™ technology platform.
Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance
Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox™ technology platform, established a strategic cancer research alliance network, the Illuminox Alliance Institutes (IAI), in order to advance the development of new cancer therapies.
Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco.
Rakuten Medical appoints David Chao and Kentaro Hyakuno to its Board of Directors, Welcomes new CFO and General Counsel to Executive Leadership Team
Rakuten Medical has appointed two new directors to the company's Board: David Chao, co-founder and General Partner of DCM Ventures; and Kentaro Hyakuno, Chief Operating Officer and Group Executive Vice President of Rakuten, Inc.
It was another busy week for clinical trials. Here’s a look.
Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
Two posters were presented during the European Society for Medical Oncology (ESMO) Congress 2019 on its RM-1929 photoimmunotherapy (PIT) treatment in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)
8/2/2019Rakuten Medical was formerly called Aspyrian Therapeutics. Since launching in 2015, it has raised almost $500 million.
Rakuten Medical Secures Additional Investment from Rakuten to Further Develop its Photoimmunotherapy Platform Capabilities
Rakuten Medical, Inc., a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy (PIT) platform, has raised approximately US $100 million on July 31, 2019, i
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity
Rakuten Medical announces positive data results from its Phase 2a study, evaluating the safety and anti-tumor activity of RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma.
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence
Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary photoimmunotherapy platform, has established new office locations in both Amsterdam, Netherlands and Taipei, Taiwan to further strengthen its position in these geographic areas.
Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 - June 4, 2019 in Chicago
Rakuten Medical, a clinical-stage biotechnology company developing precision-targeted cancer therapies based on its proprietary photoimmunotherapy platform, will be presenting data from its Phase 2a clinical trial focused on RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma during the ASCO annual meeting, May 31 – June 4, 2019 in Chicago.
Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, announced that it has changed its name to Rakuten Medical, Inc.
Rakuten Aspyrian today announced that it has raised an additional $134 million in a second tranche of its Series C financing, bringing the total amount raised to $284 million.
Rakuten Aspyrian, announced that enrollment is underway in its global, pivotal Phase 3 clinical trial evaluating lead product candidate ASP-1929 in patients with recurrent local regional head and neck squamous cell carcinomas (HNSCC).